Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

por Budde, Lihua E., Assouline, Sarit, Sehn, Laurie H., Schuster, Stephen J., Yoon, Sung-Soo, Yoon, Dok Hyun, Matasar, Matthew J., Bosch, Francesc, Kim, Won Seog, Nastoupil, Loretta J., Flinn, Ian W., Shadman, Mazyar, Diefenbach, Catherine, O'Hear, Carol, Huang, Huang, Kwan, Antonia, Lin, Chi-Chung, Piccione, Emily C., Wei, Michael C., Yin, Shen, Barlett, Nancy L.
Publicado 2022